AR‐V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration‐resistant prostate cancer patients

• DOI: 10.1002/pros.23501
• Publication Date: 2018-03-06T04:06:42Z
• Authors: Takatsugu Okegawa; Naoki Ninomiya; Kazuki Masuda; Yu Nakamura; Mitsuhiro Tambo; Kikuo Nutahara
• Keywords: Enzalutamide; Abiraterone acetate; Circulating tumor cell

Objective We examined whether androgen receptor splice variant 7 (AR‐V7) in circulating tumor cell(CTC)clusters can be used to predict survival patients with bone metastatic castration resistant‐prostate cancer (mCRPC) treated abiraterone or enzalutamide. Methods retrospectively enrolled 98 CRPC on enzalutamide, and investigated the prognostic value of CTC cluster detection (+ v −) AR‐V7 using a − based mRNA assay. ≤50% prostate‐specific antigen (PSA) responses, PSA progression‐free (PSA‐PFS), clinical radiological (radiologic PSF), overall (OS). then assessed expression clusters identified after On‐chip multi‐imaging flow cytometry was related disease progression first‐line systemic therapy. Results All abiraterone‐treated enzalutamide‐treated received prior docetaxel. The median follow‐up 20.7 (range: 3.0‐37.0) months enzalutamide cohorts, respectively. Forty‐nine men (50.0%) were (−), 23 (23.5%) cluster(+)/AR‐V7(−), 26 (26.5%) cluster(+)/AR‐V7(+). cluster(+)/AR‐V7(+) more likely have EOD ≥3 at diagnosis ( P = 0.003), pain 0.023), higher alkaline phosphatase levels < 0.001), visceral metastases 0.001). On multivariable analysis, pretherapy cluster(+), ALP >UNL independently associated poor PSA‐PFS, radiographic PFS, OS patients. Conclusion AR‐V7‐positive detected important for assessing response therapy predicting outcome.